CN1625393A - 治疗耳鸣的α2δ配体 - Google Patents

治疗耳鸣的α2δ配体 Download PDF

Info

Publication number
CN1625393A
CN1625393A CNA038031388A CN03803138A CN1625393A CN 1625393 A CN1625393 A CN 1625393A CN A038031388 A CNA038031388 A CN A038031388A CN 03803138 A CN03803138 A CN 03803138A CN 1625393 A CN1625393 A CN 1625393A
Authority
CN
China
Prior art keywords
aminomethyl
methyl
acid
acetic acid
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038031388A
Other languages
English (en)
Chinese (zh)
Inventor
戴维·J·多利
戴维·J·伍斯特罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27663234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1625393(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CN1625393A publication Critical patent/CN1625393A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNA038031388A 2002-01-31 2003-01-20 治疗耳鸣的α2δ配体 Pending CN1625393A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35363202P 2002-01-31 2002-01-31
US60/353,632 2002-01-31

Publications (1)

Publication Number Publication Date
CN1625393A true CN1625393A (zh) 2005-06-08

Family

ID=27663234

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038031388A Pending CN1625393A (zh) 2002-01-31 2003-01-20 治疗耳鸣的α2δ配体

Country Status (16)

Country Link
US (2) US7026505B2 (https=)
EP (1) EP1469841A1 (https=)
JP (1) JP2005521664A (https=)
KR (1) KR20040081478A (https=)
CN (1) CN1625393A (https=)
AU (1) AU2003201716B2 (https=)
BR (1) BR0307411A (https=)
CA (1) CA2474000A1 (https=)
CL (1) CL2008000613A1 (https=)
IL (1) IL162028A0 (https=)
MX (1) MXPA04004105A (https=)
NZ (1) NZ532624A (https=)
PL (1) PL371944A1 (https=)
TW (1) TW200306177A (https=)
WO (1) WO2003063845A1 (https=)
ZA (1) ZA200403069B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101260063A (zh) * 2008-03-21 2008-09-10 北京润德康医药技术有限公司 γ-氨基丁酸衍生物及其制备方法
CN111718379A (zh) * 2019-03-19 2020-09-29 海南长安国际制药有限公司 具有l1和l2结构的铂类物质及其制备方法和应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2004078734A1 (en) 2003-03-07 2004-09-16 Warner-Lambert Company Llc TETRAZOLE AND OXADIAZOLONE SUBSTITUTED β-AMINO ACID DERIVATIVES
NZ543102A (en) 2003-04-24 2008-12-24 Incyte Corp Aza spiro alkane derivatives as inhibitors of metalloproteases
WO2005013888A2 (en) * 2003-05-14 2005-02-17 Cytokinetics, Inc. Compounds, compositions and methods
CN101506140B (zh) * 2006-08-24 2014-06-18 百时美施贵宝公司 环状11β-羟类固醇脱氢酶Ⅰ型抑制剂
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US20080188562A1 (en) * 2006-11-14 2008-08-07 Noa Zerangue Treating tinnitus using prodrugs of gabapentin and pregabalin
WO2008073257A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
ITMI20071492A1 (it) 2007-07-24 2009-01-25 S I I T Srl Servizio Internazi "composizioni per il trattamento e la prevenzione di condizioni di vertigine e acufeni comprendenti citicolina, estratto di ginkgo biloba e flavoni dimerici di ginkgo biloba"
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
ATE361909T1 (de) * 1996-10-23 2007-06-15 Warner Lambert Co Substituierte gamma-aminobuttersäurederivate als arzneimittel
CA2304967C (en) * 1997-12-16 2005-06-14 Warner-Lambert Company 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
SI1045839T1 (en) * 1997-12-16 2004-06-30 Warner-Lambert Company Llc Novel amines as pharmaceutical agents
CN1131855C (zh) * 1997-12-16 2003-12-24 沃尼尔·朗伯公司 1－取代－1－氨基甲基－环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途
WO1999061424A1 (en) * 1998-05-26 1999-12-02 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
ES2317839T3 (es) * 1999-06-10 2009-05-01 Warner-Lambert Company Llc Acidos 3-propil gamma-aminobutiricos monosustituidos.
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
US6620829B2 (en) * 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101260063A (zh) * 2008-03-21 2008-09-10 北京润德康医药技术有限公司 γ-氨基丁酸衍生物及其制备方法
CN101260063B (zh) * 2008-03-21 2013-06-19 北京润德康医药技术有限公司 γ-氨基丁酸衍生物及其制备方法
CN111718379A (zh) * 2019-03-19 2020-09-29 海南长安国际制药有限公司 具有l1和l2结构的铂类物质及其制备方法和应用

Also Published As

Publication number Publication date
MXPA04004105A (es) 2004-11-29
BR0307411A (pt) 2004-12-07
IL162028A0 (en) 2005-11-20
US7026505B2 (en) 2006-04-11
CL2008000613A1 (es) 2008-11-07
WO2003063845A1 (en) 2003-08-07
EP1469841A1 (en) 2004-10-27
KR20040081478A (ko) 2004-09-21
ZA200403069B (en) 2005-04-22
NZ532624A (en) 2007-05-31
JP2005521664A (ja) 2005-07-21
PL371944A1 (en) 2005-07-11
CA2474000A1 (en) 2003-08-07
US20060100281A1 (en) 2006-05-11
TW200306177A (en) 2003-11-16
US7138542B2 (en) 2006-11-21
AU2003201716B2 (en) 2008-04-17
US20030176504A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
CN1726023A (zh) 用于治疗纤维肌痛和其它疾病的普加巴林衍生物
CN1196671C (zh) 单和双取代的3－丙基－γ－氨基丁酸
CN1243723C (zh) 作为fsad的nep抑制剂的n－苯丙基环戊基取代的戊二酰胺衍生物
CN1625393A (zh) 治疗耳鸣的α2δ配体
CN1303991C (zh) γ－氨基丁酸衍生物的稳定药物制剂和其制备方法
CN1438991A (zh) 作为中性内肽酶的抑制剂的环戊基－取代的戊二酰胺衍生物
CN1878546A (zh) 治疗抑郁症和焦虑症的包括α－2δ配体和SSRI和/或SNRI的联用药物
CN1626069A (zh) 支链氨基酸依赖性氨基转移酶的抑制剂及其在治疗糖尿病性视网膜病中的应用
CN1849153A (zh) 含有α－2－δ配体和5－羟色胺/去甲肾上腺素重摄取抑制剂的组合物
US7381747B2 (en) Alpha 2 delta ligands for post-traumatic stress disorder
CN1556698A (zh) 使用选择性iNOS抑制剂的神经保护治疗方法
CN1856301A (zh) 治疗性β－氨基酸
CN1610544A (zh) 用于预防和治疗内脏疼痛和胃肠疾病的方法
HK1074165A (en) Alpha 2 delta ligands to treat tinnitus
AU2003303040B2 (en) Pregabalin derivatives for the treatment of fibromyalgia and other disorders
CN1443190A (zh) 基质金属蛋白酶抑制剂
HK1082410A (en) Pregabalin derivatives for the treatment of fibromyalgia and other disorders
CN1674885A (zh) 治疗和预防胃肠病症的方法
CN1556707A (zh) 使用选择性iNOS抑制剂的眼科疾病治疗方法
HK1076626B (en) Mono-and disubstituted 3-propyl gamma-aminobutyric acids
HK1092089A (en) Combinations comprising alpha-2-delta ligands and serotonin/noradrenaline re-uptake inhibitors
HK1092378A (en) Therapeutic beta aminoacids
HK1057563A (en) Matrix metalloproteinase inhibitors
HK1083589A (en) Alpha2delta ligands for different pharmaceutical uses
HK1079429A (en) Methods for treatment and prevention of gastrointestinal conditions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1074165

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1074165

Country of ref document: HK